STIM (Neuronetics) 1-Year Share Buyback Ratio : -91.40% (As of Dec. 2024 )

View and export this data going back to 2018. Start your Free Trial

What is Neuronetics 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Neuronetics's current 1-Year Share Buyback Ratio was -91.40%.

STIM's 1-Year Share Buyback Ratio is ranked worse than
90.56% of 572 companies
in the Medical Devices & Instruments industry
Industry Median: -2.6 vs STIM: -91.40

Competitive Comparison of Neuronetics's 1-Year Share Buyback Ratio

For the Medical Devices subindustry, Neuronetics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuronetics's 1-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Neuronetics's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Neuronetics 1-Year Share Buyback Ratio Calculation

Neuronetics's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(29.091	-	55.680)	/	29.091
	=	-91.4%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuronetics (NAS:STIM) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Neuronetics 1-Year Share Buyback Ratio Related Terms

Neuronetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neuronetics Inc (NAS:STIM) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Executives

Stephen Furlong	officer: CFO	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
William Andrew Macan	officer: Sr. VP, GC, CCO and Secretary	24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Keith J Sullivan	director, officer: President and CEO	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Robert Cascella	director	C/O HOLOGIC, INC., BEDFORD MA 01730
Glenn P Muir	director	C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell	director	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc	10 percent owner	245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper	director	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook	director	162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Gregory Harper	officer: VP of Prod. Dev. & Operations	C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley	director	2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie	officer: Chief Commercial Officer	C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355